Haemonetics to Acquire Cardiva Medical for ~$510M
Shots:
- Cardiva to receive $475M up front and up to an additional ~$35M in contingent consideration based on sales growth. The transaction is expected to be completed in Q1’21
- The acquisition expands Haemonetics’ blood transfusion and loss management offerings and enhance its penetration into the large and growing interventional cardiology and electrophysiology markets
- Cardiva's portfolio includes two catheter-based vascular access site closure devices used to help seal up access sites following minimally invasive interventions and diagnostic procedures. Both devices employ a collapsible disc in different sizes to deliver a collagen patch to achieve hemostasis
Ref: PRNewswire| Image: Cardiva
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com